Samsung Biologics has reached an agreement to produce a potential coronavirus treatment on behalf of Vir Biotechnology, with output scaled up in 2021 pending clearance from health authorities, reported the Nikkei Asian Review.
Under the $362-million deal with Vir, Samsung Biologics will manufacture antibody treatments that have received preliminary approval from the FDA, with clinical trials set to begin within the year.
"Our expectation is that there will be a significant need around the world for antibody therapies," commented Vir CEO George Scangos.
"Accordingly, we are taking proactive steps to reserve large-scale manufacturing capacity to be ready to move quickly with any of our antibody candidates that prove to be clinically safe and effective," he added.
Samsung Biologics will shift to mass production at a facility in Incheon, South Korea, next year after the treatment is approved by health authorities in various countries.
Meanwhile, citing support by the Trump administration, a company official said "the high likelihood that Vir's treatment candidates will be approved for the coronavirus" led to the agreement.
To read more NewsPoints articles, click here.